{
    "root": "2f8b2a36-ac60-7762-e063-6294a90ae573",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Glycopyrrolate",
    "value": "20250304",
    "ingredients": [
        {
            "name": "DIBASIC CALCIUM PHOSPHATE DIHYDRATE",
            "code": "O7TSZ97GEP"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "GLYCOPYRROLATE",
            "code": "V92SO9WP2I"
        }
    ],
    "indications": "glycopyrrolate tablets indicated adults reduce symptoms peptic ulcer adjunct treatment peptic ulcer . limitations glycopyrrolate tablets indicated monotherapy treatment peptic ulcer effectiveness peptic ulcer healing established .",
    "contraindications": "2.1 important dosing information • glycopyrrolate tablets 2 mg recommended patients lower strength oral glycopyrrolate ( e.g . , glycopyrrolate tablets 1 mg another 1 mg tablet strength ) appropriate initial maintenance treatment strength glycopyrrolate tablets may exceed recommended initial maintenance oral glycopyrrolate tablets . 2.2 recommended • recommended initial glycopyrrolate tablets 1 mg adults 1 mg three times daily ( morning , early afternoon , bedtime ) . patients may require 2 mg bedtime assure overnight control symptoms . maintenance , 1 mg twice day frequently adequate . • recommended glycopyrrolate tablets 2 mg adults 2 mg two three times daily equally spaced intervals . • maximum recommended daily glycopyrrolate 8 mg. • lowest effective glycopyrrolate control symptoms . patients titrated lower dose , switch glycopyrrolate tablets 2 mg glycopyrrolate tablets 1 mg another 1 mg oral tablet glycopyrrolate .",
    "warningsAndPrecautions": "glycopyrrolate tablets usp , 1 mg white off-white , round , beveled edge uncoated tablets , debossed ‘ ’ break line one side ‘ 08 ’ side . ndc 50268-363-15 ( 10 tablets per card , 5 cards per carton ) glycopyrrolate tablets usp , 2 mg white off-white , round , beveled edge uncoated tablets , debossed ‘ ’ break line one side ‘ 51 ’ side . store 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . dispensed unit dose packaging . institutional . keep medication reach children . dispense tight container .",
    "adverseReactions": "glycopyrrolate tablets contraindicated : • patients risk anticholinergic toxicity due underlying medical condition , including : • glaucoma [ ( 5.1 ) ] • obstructive uropathies , including prostatic hypertrophy • mechanical obstructive diseases gastrointestinal tract ( e.g . , pyloroduodenal stenosis , strictures ) [ ( 5.2 ) ] • gastrointestinal motility disorders ( e.g . , achalasia , paralytic ileus , intestinal atony ) [ ( 5.3 ) ] • bleeding gastrointestinal ulcer • active inflammatory infectious colitis lead toxic megacolon • history current toxic megacolon myasthenia gravis • patients hypersensitivity glycopyrrolate inactive ingredients glycopyrrolate tablets [ ( 6 ) description ( 11 ) ] .",
    "indications_original": "Glycopyrrolate tablets are indicated in adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer.\n                  \n                  Limitations of Use\n  \nGlycopyrrolate tablets are not indicated as monotherapy for the treatment of peptic ulcer because effectiveness in peptic ulcer healing has not been established.",
    "contraindications_original": "2.1 Important Dosing Information\n  \n• Glycopyrrolate tablets 2 mg are not recommended for patients in whom a lower dosage strength of oral glycopyrrolate (e.g., glycopyrrolate tablets 1 mg or another 1 mg tablet strength) is appropriate for initial or maintenance treatment because the dosage strength of glycopyrrolate tablets may exceed the recommended initial and maintenance dosage of oral\n  \nglycopyrrolate tablets.\n \n                  \n                  2.2 Recommended Dosage\n  \n• The recommended initial dosage of glycopyrrolate tablets 1 mg for adults is 1 mg three times daily (in the morning, early afternoon, and at bedtime). Some patients may require 2 mg at bedtime to assure overnight control of symptoms. For maintenance, a dosage of 1 mg twice a day is frequently adequate.\n  \n• The recommended dosage of glycopyrrolate tablets 2 mg for adults is 2 mg two or three times daily at equally spaced intervals.\n  \n• The maximum recommended daily dosage of glycopyrrolate is 8 mg.\n  \n• Use the lowest effective dosage of glycopyrrolate to control symptoms. If patients can be titrated to a lower dose, switch from glycopyrrolate tablets 2 mg to glycopyrrolate tablets 1 mg or another 1 mg oral tablet of glycopyrrolate.",
    "warningsAndPrecautions_original": "Glycopyrrolate tablets USP, 1 mg are white to off-white, round, beveled edge uncoated tablets, debossed with ‘Y’ and break line on one side and ‘08’ on the other side.\n  \nNDC 50268-363-15 (10 tablets per card, 5 cards per carton)\n \n                  \n                  Glycopyrrolate tablets USP, 2 mg are white to off-white, round, beveled edge uncoated tablets, debossed with ‘Y’ and break line on one side and ‘51’ on the other side.\n                  \n                  Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature].\n  \nDispensed in Unit Dose Packaging. For institutional Use Only. Keep this and all medication out of the reach of children.\n  \nDispense in a tight container.",
    "adverseReactions_original": "Glycopyrrolate tablets are contraindicated in:\n  \n• Patients at risk for anticholinergic toxicity due to an underlying medical condition, including:\n  \n• Glaucoma [see Warnings and Precautions (5.1)]\n  \n• Obstructive uropathies, including prostatic hypertrophy\n  \n• Mechanical obstructive diseases of the gastrointestinal tract (e.g., pyloroduodenal stenosis, strictures) [see Warnings and Precautions (5.2)]\n  \n• Gastrointestinal motility disorders (e.g., achalasia, paralytic ileus, intestinal atony) [see Warnings and Precautions (5.3)]\n  \n• Bleeding gastrointestinal ulcer\n  \n• Active inflammatory or infectious colitis which can lead to toxic megacolon\n  \n• History of or current toxic megacolon or Myasthenia gravis\n  \n• Patients with a hypersensitivity to glycopyrrolate or any of the inactive ingredients in glycopyrrolate tablets [see Adverse Reactions (6) and Description (11)]."
}